Author/Authors :
Descourt, Renaud Institut De Canc ́erologie - CHU Morvan - Brest 29200, France , Philippe, Elo ̈ıse Institut De Canc ́erologie - CHU Morvan - Brest 29200, France , Robinet, Gilles Institut De Canc ́erologie - CHU Morvan - Brest 29200, France , Qu ́er ́e, Gilles Institut De Canc ́erologie - CHU Morvan - Brest 29200, France , Barnier, Aude Service De Pneumologie - EA3878-GETBO - Universit ́e De Bretagne Occidentale - CHU Cavale Blanche - Boulevard Tanguy-Prigent - Brest 29200, France , Menguy, Juliette Service De Pneumologie - EA3878-GETBO - Universit ́e De Bretagne Occidentale - CHU Cavale Blanche - Boulevard Tanguy-Prigent - Brest 29200, France , Couturaud, Francis Service De Pneumologie - EA3878-GETBO - Universit ́e De Bretagne Occidentale - CHU Cavale Blanche - Boulevard Tanguy-Prigent - Brest 29200, France
Abstract :
Henoch–Sch ̈onlein purpura (HSP) is an uncommon syndrome that mostly occurs in children, in whom it isfrequently triggered by infections. In contrast, HSP in adults is more frequently of neoplastic origin.CasePresentation. We reportHSP associated with a locally advanced lung squamous cell carcinoma that was considered a paraneoplastic syndrome. Systemiccorticosteroids were given because a kidney biopsy revealed active glomerulonephritis. Concomitant chemoradiotherapy achieveda partial response of the lung tumor. Consolidation immunotherapy (programmed death protein-1-ligand-1 (PD-L1) inhibitor)was cancelled because HSP is known to be an autoimmune vasculitis, and long-term corticosteroid therapy was pursued.Conclusion. Further prospective studies are needed to evaluate the effect of anti-PD-(L) 1 immunotherapies onautoimmune manifestations.
Keywords :
Henoch–Sch ̈onlein Purpura Associated , Lung Cancer , Paraneoplastic Manifestations Impede Oncological Management , Henoch–Sch ̈onlein purpura (HSP) , SCC , PD-L1